health

  By: Mr. Deepak Sharma, Co-Founder & CEO, MedLern Driven by government programs and private sector innovation, India’s healthcare journey is ripe with opportunity to leapfrog longstanding barriers through digital transformation. Landmark initiatives such as […]

An analysis of the 2025 AHA/ACC hypertension guidelines found that under the new guidelines, about 11% of adults ages 65 to 79 with stage I hypertension would no longer qualify for blood pressure medication, a […]

American College of Physicians (ACP) is warning that recent federal changes to introduce a new, more limited vaccination schedule for US children based on the Danish childhood vaccine schedule abandons long‑standing, science‑based standards and could […]

Mumbai, Mar 23: Alkem Laboratories Ltd. announced the launch of semaglutide injection in India under the brand names “Semasize”, Obesema” and “Hepaglide”. Semaglutide is administered as a subcutaneous injection, once weekly. The company has launched its […]

Sets a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at ₹325 Bangalore, March 22: Glenmark Pharmaceuticals Ltd., a research-led global pharmaceutical company, has announced the launch of GLIPIQⓇ (semaglutide) in India […]

CHENNAI, MARCH 22, 2026: Indian Hotels Company (IHCL), India’s largest hospitality company, continues to advance its sustainability and social impact agenda through Paathya, its ESG+ framework. Photo caption: Dr. S. Armstrong, Vice-Chancellor Convener Committee, University of Madras, […]

Gorakhpur, March 22: Gorakhpur Mayor Manglesh Kumar Srivastava said that children from the district and adjoining areas, diagnosed with cancer, can now undergo treatment at the BRD Medical College as part of Uttar Pradesh government’s […]

New Delhi, March 21: Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity. The companies, namely Sun […]

New Delhi, Mar 21: Zydus Lifesciences Limited, an innovation-led global lifesciences company, has launched Semaglutide Injection under the brand names – SEMAGLYNTM, MASHEMATM and ALTERMETM, upon patent expiry in India. The Drug Controller General of India […]

By Ricki Arvesen  Most of the genetic risk for developing a substance use disorder comes from genes that broadly affect how our brains process rewards, regulate impulses and weigh consequences – not from genes that […]